What is the revenue of Haemonetics?
Haemonetics Corporation is a prominent global healthcare company dedicated to providing advanced medical solutions, specifically focusing on blood management, plasma collection, and surgical technologies. According to recent financial reports and trailing twelve-month data as of mid-2026, Haemonetics reported an estimated revenue of approximately $1.33 billion. In Indian Rupees, this translates to roughly ₹115 billion to ₹126.87 billion, demonstrating consistent and robust top-line growth over previous fiscal periods. The company generates its substantial revenue streams primarily through its diverse portfolio of comprehensive blood and plasma solutions. These include plasma collection systems, hospital blood management software, and various specialized surgical devices that are essential for patient care and critical medical procedures worldwide. Haemonetics maintains its strong financial standing and continuous revenue growth by constantly innovating its product offerings, expanding its global footprint across international medical markets, and securing long-term contracts with major healthcare providers, hospitals, and commercial plasma collection centers. The company's ability to navigate complex medical supply chain demands while ensuring the delivery of high-quality, life-saving medical equipment solidifies its financial stability and consistent annual revenue generation in the highly competitive healthcare technology sector.
Related FAQs
Haemonetics functions primarily as a specialized medical technology and healthcare equipment manufacturing enterprise rather than a traditional drug-discovery biotechnology firm.
Haemonetics Corporation maintains a strong reputation as an innovative healthcare technology and medical device enterprise dedicated to providing advanced solutions for blood and plasma collection, surgical hemostasis, and hospital transfusion manage...
Hagerty’s standard collector car insurance is designed to provide coverage for vehicle loss or damage resulting from accidents, fire, theft, or natural disasters, but it does not typically cover mechanical breakdowns or engine failures due to normal ...
Hana Bank is a colossal, premier commercial banking institution headquartered in Seoul, South Korea, operating as a flagship subsidiary under the Hana Financial Group.
Equity research analysts covering Haemonetics Corporation (HAE) maintain a favorable consensus rating, predominantly leaning toward a buy recommendation based on the company's strong positioning within the global medical device, blood management, and...
Hawkins Inc (HWKN) has demonstrated stellar and resilient stock performance recently, trading strongly within the upper tier of its 52-week range and rewarding long-term shareholders.
Haemonetics Corporation was officially founded in 1971 by visionary biomedical inventor Dr. Allen Latham, Jr., who revolutionized blood processing technology by developing the world's first automated blood separator.
Haemonetics Corporation (HAE) is a global healthcare company that provides innovative medical solutions for blood management. Its products and services are used for blood collection, testing, separation, and transfusion processes.
Haemonetics Corporation is frequently evaluated by healthcare sector analysts as a solid long-term investment, supported by steady demand for its specialized blood management technologies, plasma collection systems, and hospital surgical solutions.
Harmonic Drive SE maintains a specialized industrial manufacturing workforce of approximately one,three hundred eighty employees focusing on high-precision gear solutions, drive mechanisms, and motion control components.
Haemonetics (HAE) stock has shown significant performance over the past year, reflecting its growth in the medical technology sector. As of August 2, 2026, the stock was trading at $85.54, with a 52-week trading range spanning from $47.32 to $87.32.